Clinical pharmacology of Taxol
- PMID: 7912527
Clinical pharmacology of Taxol
Abstract
Taxol is the first novel antimicrotubule agent approved for clinical use since the vinca alkaloids in the 1960s and may be one of the most important antineoplastic agents to emerge over the last two decades. Significant antitumor activity has been noted in ovarian, breast, lung, and head and neck cancers. This report reviews the clinical pharmacology of Taxol based on early developmental trials of the agent administered on various intravenous schedules as a single agent and in combination with other antineoplastic agents, as well as via the intraperitoneal route. In addition, available information pertaining to the pharmaco-dynamic and metabolic profiles of Taxol are discussed. Such information may be useful in designing rational treatment approaches with Taxol either as monotherapy or in chemotherapy combinations, potentially resulting in the optimal use of this important agent in cancer chemotherapeutics.
Similar articles
-
The clinical pharmacology of paclitaxel (Taxol).Semin Oncol. 1993 Aug;20(4 Suppl 3):16-25. Semin Oncol. 1993. PMID: 8102014 Review.
-
Clinical pharmacology and metabolism of Taxol (paclitaxel): update 1993.Ann Oncol. 1994;5 Suppl 6:S7-16. Ann Oncol. 1994. PMID: 7865438 Review.
-
[Paclitaxel (taxol): a review of its antitumor activity and toxicity in clinical studies].Gan To Kagaku Ryoho. 1998 Mar;25(4):605-15. Gan To Kagaku Ryoho. 1998. PMID: 9530372 Review. Japanese.
-
Paclitaxel combination therapy in the treatment of metastatic breast cancer: a review.Semin Oncol. 1996 Oct;23(5 Suppl 11):46-56. Semin Oncol. 1996. PMID: 8893900 Review.
-
Paclitaxel (Taxol)/doxorubicin combinations in advanced breast cancer: the Eastern Cooperative Oncology Group experience.Semin Oncol. 1994 Oct;21(5 Suppl 8):15-8. Semin Oncol. 1994. PMID: 7939756 Clinical Trial.
Cited by
-
The distribution and retention of paclitaxel and doxorubicin in multicellular layer cultures.Oncol Rep. 2012 Apr;27(4):995-1002. doi: 10.3892/or.2012.1650. Epub 2012 Jan 20. Oncol Rep. 2012. PMID: 22267208 Free PMC article.
-
In vitro and in vivo Assessment of Keratose as a Novel Excipient of Paclitaxel Coated Balloons.Front Pharmacol. 2018 Jul 30;9:808. doi: 10.3389/fphar.2018.00808. eCollection 2018. Front Pharmacol. 2018. PMID: 30104972 Free PMC article.
-
Noncovalent interaction-assisted drug delivery system with highly efficient uptake and release of paclitaxel for anticancer therapy.Int J Nanomedicine. 2017 Sep 25;12:7039-7051. doi: 10.2147/IJN.S144322. eCollection 2017. Int J Nanomedicine. 2017. PMID: 29026300 Free PMC article.
-
Inhibition of Bcl-xL sensitizes cells to mitotic blockers, but not mitotic drivers.Open Biol. 2016 Aug;6(8):160134. doi: 10.1098/rsob.160134. Open Biol. 2016. PMID: 27512141 Free PMC article.
-
A Review of Paclitaxel and Novel Formulations Including Those Suitable for Use in Dogs.J Vet Intern Med. 2015 Jul-Aug;29(4):1006-12. doi: 10.1111/jvim.12596. J Vet Intern Med. 2015. PMID: 26179168 Free PMC article. Review.